Recent Updates
Recently added Catalysts
ZLAB Positive Sentiment

Zai Lab Announces First-Time Inclusion of KarXT and VYVGART Hytrulo® in China’s 2026 National Reimbursement Drug List, Expanding Access to Key Growth Products

Saturday, November 14, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Zai Lab announced that five of its medicines have been included in China's 2026 National Reimbursement Drug List. This includes first-time listings for KarXT and VYVGART Hytrulo®, enhancing access for patients with generalized Myasthenia Gravis and schizophrenia. Additionally, three products received renewals, ensuring continued access in oncology and infectious disease.

Market Sentiment Analysis

POSITIVE FACTORS

  • Five medicines included in China's NRDL.
  • First-time listings for KarXT and VYVGART Hytrulo®.
  • Increased patient access to important treatments.
  • Renewals for oncology and infectious disease products.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+58%
120-day peak, hindsight
Typical move
4.3%
average across 15 past catalysts
Cash runway
~29 mo
Low dilution risk
Lead asset
ZL-1310
Phase 3 · Extensive-Stage Small Cell Lung Cancer

Full Press Release Details

SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovation-driven, global biopharma company, today announced that five of its commercial medicines in China have been included in the country’s 2026 National Reimbursement Drug List (NRDL). The update includes two first-time listings, expanding patient access to treatments for gMG and schizophrenia, and three renewals, which maintain access across oncology and infectious disease. Zai Lab Products Newly

Frequently Asked Questions

What is the National Reimbursement Drug List?

The NRDL is a list of medicines covered by China's national health insurance.

Which products did Zai Lab include in the NRDL?

Zai Lab included KarXT, VYVGART, and three other medicines in the NRDL.

What conditions do KarXT and VYVGART treat?

KarXT is for generalized Myasthenia Gravis, and VYVGART treats schizophrenia.

How does NRDL inclusion affect patients?

Inclusion in the NRDL improves patient access to essential treatments.

ShareAdd on Google
Tags: ZLAB Zai Lab KarXT VYVGART China NRDL biopharma
Last updated: Nov 14, 2026

Biotech snapshot

Cash runway
$560M liquidity · $19M/mo burn
~29 mo
Low dilution risk
Lead asset
ZL-1310Phase 3
Extensive-Stage Small Cell Lung Cancer →

Catalyst track record

+58%
best trade around ZLAB's most recent catalyst

Peak hindsight return over a 120-day window, across 15 tracked FDA/PDUFA catalysts for ZLAB.

See every catalyst's timing & PoA →